The short answer
In the Ozempic vs Wegovy vs Zepbound comparison, two of the three drugs share one ingredient. Ozempic and Wegovy are both semaglutide from Novo Nordisk, while Zepbound is tirzepatide from Eli Lilly. In the only head-to-head trial so far, people on Zepbound lost more weight on average than people on Wegovy. Even so, the right choice depends on your diagnosis, your coverage and how you tolerate side effects.
- Ozempic: approved for type 2 diabetes (blood sugar, heart and kidney protection), not for weight loss on its own.
- Wegovy: approved for chronic weight management, heart-risk reduction in people with heart disease, and a type of fatty liver disease (MASH). It comes as a weekly shot or a daily pill.
- Zepbound: approved for chronic weight management and obstructive sleep apnea in adults with obesity.
- Weight loss in trials: about 20% with Zepbound vs about 14% with Wegovy in the SURMOUNT-5 head-to-head trial.
- Next step: all three need a prescription, so talk to your doctor about which one fits your health history.
20.2%
Average weight loss on tirzepatide (Zepbound) in SURMOUNT-5
13.7%
Average weight loss on semaglutide (Wegovy) in the same trial
72 weeks
Length of the head-to-head trial
$50/mo
Medicare GLP-1 Bridge copay, July 2026 to December 2027
In this article
If you are weighing Ozempic vs Wegovy vs Zepbound, you are really comparing two molecules. Semaglutide (the active drug in Ozempic and Wegovy) is a GLP-1 receptor agonist, meaning it mimics a gut hormone called glucagon-like peptide-1 that tells your brain you are full and helps regulate blood sugar. Tirzepatide (the active drug in Zepbound) acts on the GLP-1 receptor and also on the GIP receptor, a second gut hormone pathway involved in appetite and insulin release, according to the FDA.
This guide sticks to what the FDA labels, the major clinical trials and the drugmakers’ own price pages say as of October 2026. For a deeper look at how these medicines act on appetite, digestion and the rest of your body, see our GLP-1 drugs explainer. Nothing here replaces advice from the clinician who knows your history.
What are Ozempic, Wegovy and Zepbound?
They are three brand-name, once-weekly injectable prescription medicines from the same broad drug family, but they are not interchangeable. Two share an ingredient, and each has its own set of FDA-approved uses.
Ozempic (semaglutide) by Novo Nordisk
Ozempic is a diabetes medicine. According to MedlinePlus, semaglutide is used to control blood sugar in adults with type 2 diabetes, lower the risk of heart attack and stroke in adults with type 2 diabetes and heart disease, and slow kidney disease in certain adults with type 2 diabetes. Doctors sometimes prescribe it off-label for weight, but weight loss is not its approved use.
Wegovy (semaglutide) by Novo Nordisk
Wegovy contains the same semaglutide as Ozempic, yet it is dosed and approved for chronic weight management. As a result, its label also covers reducing heart attack and stroke risk in adults with overweight or obesity and established heart disease, plus treating noncirrhotic MASH, a fatty liver disease with scarring. In 2026 it is sold as a weekly pen, a higher-dose Wegovy HD pen and a daily pill.
Zepbound (tirzepatide) by Eli Lilly
Zepbound is tirzepatide approved for weight. The FDA approved it in November 2023 for chronic weight management, then in December 2024 it became the first drug approved for moderate to severe obstructive sleep apnea in adults with obesity. Mounjaro, which people often mention in the same breath, is the same tirzepatide sold for type 2 diabetes.
Pro tip. Same ingredient does not mean same prescription. Insurers usually cover Ozempic only for type 2 diabetes and Wegovy or Zepbound only when the plan covers weight-loss drugs, so the brand your doctor writes can change what you pay.
Ozempic vs Wegovy vs Zepbound at a glance
Here is the Ozempic vs Wegovy vs Zepbound picture in one table. The weight-loss figures come from each drug’s main trial, so they are not a direct ranking except where noted.
| Ozempic | Wegovy | Zepbound | |
|---|---|---|---|
| Active drug | Semaglutide | Semaglutide | Tirzepatide |
| Maker | Novo Nordisk | Novo Nordisk | Eli Lilly |
| How it works | GLP-1 | GLP-1 | GLP-1 and GIP |
| Main approved use | Type 2 diabetes | Chronic weight management | Chronic weight management |
| Other approved uses | Heart and kidney protection in type 2 diabetes | Heart-risk reduction with heart disease; MASH | Obstructive sleep apnea with obesity |
| Forms | Weekly pen; daily tablet | Weekly pen, HD pen; daily pill | Weekly pen, KwikPen, vials |
| Key weight-loss trial | Not studied for weight as a primary goal | STEP 1: 14.9% at 68 weeks | SURMOUNT-1: up to 20.9% at 72 weeks |
| Head-to-head (SURMOUNT-5) | Not included | 13.7% at 72 weeks | 20.2% at 72 weeks |
Which one causes the most weight loss?
On average, Zepbound produces more weight loss than Wegovy, and Wegovy is the semaglutide product dosed for weight. That conclusion rests mainly on one large head-to-head trial, so it describes group averages rather than what will happen to you.
Is Zepbound better than Wegovy for weight loss?
In the SURMOUNT-5 trial, published in the New England Journal of Medicine in 2025, 751 adults with obesity but without diabetes took the highest tolerated dose of tirzepatide or semaglutide for 72 weeks. Weight fell by 20.2% on tirzepatide versus 13.7% on semaglutide, and waist size dropped by 18.4 cm versus 13.0 cm. In addition, people on tirzepatide were more likely to reach 10%, 15%, 20% and 25% weight loss. Eli Lilly funded the trial, which is worth knowing when you read the results.
What did the original trials show?
Each drug was first tested against placebo. In STEP 1, semaglutide 2.4 mg (the Wegovy dose) led to a 14.9% average weight loss at 68 weeks versus 2.4% on placebo. In SURMOUNT-1, tirzepatide led to 15.0%, 19.5% and 20.9% weight loss at the 5 mg, 10 mg and 15 mg doses, versus 3.1% on placebo, over 72 weeks. Meanwhile, Novo Nordisk reports a 20.7% average loss at 72 weeks with the 7.2 mg Wegovy HD dose, which the FDA approved in March 2026 for adults who already tolerate the 2.4 mg dose.
| Trial | Drug and dose | Length | Average weight change | Placebo |
|---|---|---|---|---|
| STEP 1 (2021) | Semaglutide 2.4 mg (Wegovy) | 68 weeks | -14.9% | -2.4% |
| SURMOUNT-1 (2022) | Tirzepatide 15 mg (Zepbound) | 72 weeks | -20.9% | -3.1% |
| SURMOUNT-5 (2025) | Tirzepatide vs semaglutide | 72 weeks | -20.2% vs -13.7% | None (head-to-head) |
| OASIS 4 (2025) | Oral semaglutide 25 mg (Wegovy pill) | 64 weeks | -13.6% | -2.2% |
| ATTAIN-1 (2025) | Orforglipron 36 mg (Foundayo) | 72 weeks | -11.2% | -2.1% |
What happens if you stop taking them?
Most people regain weight after stopping, which is why these drugs are treated as long-term therapy. For example, in SURMOUNT-4, people who lost about 21% on tirzepatide and then switched to placebo regained 14% of their weight over the next year, while those who stayed on the drug lost a further 5.5%. Therefore, plan for cost and side effects over years, not months.
Watch out. Weight-loss percentages in trials include a reduced-calorie diet and more physical activity. The drugs are approved as an add-on to those habits, not a replacement for them.
Because muscle and fitness still matter while appetite drops, pair any medication with movement you can keep up. Our guides on walking vs running for fat loss and losing belly fat cover the exercise side.
What is each drug FDA-approved for?
Each drug has a different label, and the label decides who can get it prescribed and covered. Ozempic is for type 2 diabetes, while Wegovy and Zepbound are for weight management and a few related conditions.
| Approved use | Ozempic | Wegovy | Zepbound |
|---|---|---|---|
| Blood sugar control in type 2 diabetes | Yes | No | No (Mounjaro is) |
| Chronic weight management | No | Yes | Yes |
| Lower heart attack and stroke risk | Yes, with type 2 diabetes and heart disease | Yes, with overweight or obesity and heart disease | No |
| Kidney disease with type 2 diabetes | Yes | No | No |
| Noncirrhotic MASH (fatty liver with scarring) | No | Yes | No |
| Obstructive sleep apnea with obesity | No | No | Yes |
Who qualifies for Wegovy or Zepbound?
For weight management, the FDA criteria are an adult BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related condition such as high blood pressure, type 2 diabetes or high cholesterol, according to the FDA. Your doctor will also check for reasons you should not take one, such as a personal or family history of medullary thyroid cancer.
Does the heart benefit apply to Zepbound?
Not on the current label. Wegovy’s heart indication comes from the SELECT trial, in which 17,604 adults with heart disease and overweight or obesity, but without diabetes, had a 20% lower risk of heart attack, stroke or cardiovascular death on semaglutide than on placebo. Zepbound has no comparable approved heart claim yet.
How do the side effects compare?
The side effects are similar because all three slow stomach emptying and dampen appetite. Stomach and gut symptoms are the most common, and they usually show up during dose increases.
Common side effects of Ozempic vs Wegovy vs Zepbound
- Gut symptoms: nausea, vomiting, diarrhea, constipation, stomach pain and burping.
- Reflux and heartburn: listed for both semaglutide and tirzepatide.
- Other: fatigue, injection-site reactions and hair loss are listed for tirzepatide; headache is listed for semaglutide.
In the SURMOUNT-5 trial, most stomach side effects in both groups were mild to moderate and happened mainly while the dose was being raised. In the OASIS 4 pill trial, by contrast, 74% of people on oral semaglutide reported gut symptoms versus 42% on placebo, so tablets are not gentler by default.
Serious warnings on the labels
All three carry a boxed warning about thyroid C-cell tumors, which appeared in rats; it is not known whether the risk applies to people. Consequently, people with a personal or family history of medullary thyroid cancer or MEN 2 should not use them, per MedlinePlus and MedlinePlus. The FDA also lists pancreatitis, gallbladder problems, low blood sugar (mainly with insulin or sulfonylureas), acute kidney injury, diabetic eye changes in people with diabetes, allergic reactions, and a risk of inhaling stomach contents during anesthesia or deep sedation.
In January 2026, the FDA asked makers to remove the suicidal thoughts and behavior warning from the Wegovy and Zepbound labels after reviewing data from 91 trials that found no higher risk. Still, tell your doctor about any mood changes.
Does Zepbound affect birth control pills?
Yes, it can. MedlinePlus notes that tirzepatide may make hormonal birth control taken by mouth less effective, so doctors may suggest a backup or non-oral method for four weeks after starting and after each dose increase. Ask your prescriber about semaglutide and any other medicines you take.
Watch out. The FDA warns against unapproved and counterfeit GLP-1 products, including compounded versions with dosing errors and “research use” products sold for people. As of its October 2026 update, it had received hundreds of adverse-event reports for compounded semaglutide and tirzepatide. Fill prescriptions only at a state-licensed pharmacy.
How much do they cost in 2026?
What you pay depends far more on your coverage than on list price. With commercial insurance that covers the drug, makers’ savings cards can bring costs to as little as $25 a month; without coverage, direct self-pay prices now run roughly $149 to $699 a month depending on drug and dose.
| Drug | Self-pay price (maker program) | Notes |
|---|---|---|
| Ozempic pen | $349/mo (0.25, 0.5, 1 mg); $499/mo (2 mg) | New patients: $199/mo for the first 2 fills through Dec 31, 2026 |
| Ozempic pill | $149, $199 or $299/mo by dose | For type 2 diabetes |
| Wegovy pen | $349/mo; Wegovy HD 7.2 mg $399/mo | New patients: $199/mo for the first 2 fills through Dec 31, 2026 |
| Wegovy pill | $149/mo (1.5 mg), $199/mo (4 mg), $299/mo (9 and 25 mg) | List price $1,349.02 per package |
| Zepbound KwikPen or vial | $299/mo (2.5 mg), $399/mo (5 mg), $449/mo (7.5 to 15 mg) | $449 tier requires a refill within 45 days; otherwise $499 to $699 |
These figures come straight from NovoCare for Wegovy, NovoCare for Ozempic and LillyDirect for Zepbound. Self-pay programs generally exclude people with government insurance, and the spending usually does not count toward your deductible.
Does Medicare cover Wegovy or Zepbound in 2026?
Partly, through a temporary program. The Medicare GLP-1 Bridge, a CMS demonstration running from July 1, 2026, to December 31, 2027, lets eligible Part D enrollees get Wegovy (pen or pill), the Zepbound KwikPen and Foundayo for $50 a month, according to a Medicare.gov fact sheet. That $50 does not count toward your Part D deductible or yearly out-of-pocket cap, and eligibility depends on BMI plus certain health conditions, so ask your doctor to check.
Why is Ozempic easier to get covered?
Because it treats a diagnosed disease. Most plans cover type 2 diabetes drugs, whereas many employer plans still exclude weight-loss medicines. However, plans can deny Ozempic if you do not have type 2 diabetes, so ask your insurer for its prior-authorization rules before you fill.
Pro tip. Before paying cash, call your insurer and ask whether Wegovy, Zepbound or Foundayo is on the formulary, what prior authorization requires and whether a savings card applies. Then compare that number to the self-pay price.
What about the new GLP-1 pills?
Yes, pills are now an option. The FDA approved the Wegovy pill (oral semaglutide 25 mg) in December 2025 and Eli Lilly’s Foundayo (orforglipron) in April 2026, both for chronic weight management in adults.
Wegovy pill vs Zepbound: which works better?
There is no head-to-head trial. In separate trials, the Wegovy pill led to 13.6% weight loss at 64 weeks and orforglipron led to 11.2% at 72 weeks at its top dose, compared with about 20% for Zepbound in SURMOUNT-1. Even so, a daily pill may suit people who dislike needles, and pricing starts lower. Ask your pharmacist how to time a daily GLP-1 pill around meals, because the instructions differ by product.
Foundayo self-pay prices on LillyDirect start at $149 a month for the lowest doses and reach $299 a month for higher doses. In addition, Ozempic now has a tablet version for type 2 diabetes, which replaced the older Rybelsus brand name.
How to choose with your doctor
The best choice is the one that fits your diagnosis, your other health conditions and your budget, and you will make it with your prescriber. These questions can help shape that conversation.
Ozempic: Best fit if you have type 2 diabetes
If blood sugar control is the main goal, Ozempic is approved for it and adds heart and kidney protection for some patients. Weight loss is a likely side benefit, not the labeled purpose.
- Approved for: type 2 diabetes, heart and kidney risk in type 2 diabetes
- Forms: weekly pen or daily tablet
- Coverage: usually easiest with a diabetes diagnosis
Wegovy: Best fit if you also have heart disease or MASH
Wegovy is the semaglutide dose designed for weight, and it is the only one of the three with an approved heart-risk claim for people without diabetes. It also offers a pill.
- Approved for: weight management, heart-risk reduction with heart disease, MASH
- Average loss: 14.9% (STEP 1) to 20.7% (HD dose)
- Forms: weekly pen, HD pen, daily pill
Zepbound: Best fit if maximum weight loss or sleep apnea is the priority
Zepbound produced the most average weight loss in the head-to-head trial and is approved for obstructive sleep apnea with obesity. It does not yet carry a heart-risk indication.
- Approved for: weight management, obstructive sleep apnea with obesity
- Average loss: 20.2% (SURMOUNT-5)
- Forms: weekly pen, KwikPen, vials
Questions to ask your doctor
- Which of these is covered by my plan, and what does prior authorization need?
- Do my other conditions (diabetes, heart disease, sleep apnea, fatty liver) favor one drug?
- How will we manage nausea and other side effects while the dose goes up?
- Do any of my current medicines, including birth control, interact?
- What is the plan if I need to stop, and how do we keep weight off?
When to call your doctor
Call your doctor promptly if something feels wrong, and do not adjust or stop a dose on your own. Get emergency care by calling 911 for trouble breathing, swelling of the face or throat, or severe symptoms.
- Severe stomach pain that does not go away, with or without vomiting, which can spread to your back (possible pancreatitis).
- Pain in the upper right belly, fever, yellow skin or eyes, or clay-colored stools (possible gallbladder problems).
- Vomiting or diarrhea so frequent you cannot keep fluids down, or you are urinating much less (dehydration and kidney strain).
- A lump or swelling in your neck, hoarseness, trouble swallowing or shortness of breath.
- Shakiness, sweating, confusion or a racing heartbeat, especially if you also take insulin or a sulfonylurea (low blood sugar).
- Vision changes if you have diabetes.
- Rash, hives, dizziness or fainting after a dose.
Also tell any surgeon or anesthesiologist that you take one of these drugs before a procedure, because slowed stomach emptying can raise the risk during sedation.
Our verdict
For most adults focused on weight, the Ozempic vs Wegovy vs Zepbound decision comes down to Wegovy or Zepbound, since Ozempic is a diabetes medicine. Zepbound has the edge on average weight loss in the only head-to-head trial, while Wegovy brings a proven heart benefit for people with heart disease and a pill option. Ultimately, coverage, side effects and your health history should decide it, together with your doctor.
Frequently asked questions
Is Ozempic the same as Wegovy?
They contain the same active drug, semaglutide, and both come from Novo Nordisk, but they are different products. Ozempic is FDA-approved for type 2 diabetes, including heart and kidney protection in those patients. Wegovy is dosed and approved for chronic weight management, heart-risk reduction in people with heart disease, and MASH. Insurers treat them as separate drugs with separate coverage rules.
Is Zepbound stronger than Wegovy?
On average, yes for weight loss. In the SURMOUNT-5 head-to-head trial, adults without diabetes lost 20.2% of their weight on tirzepatide (Zepbound) versus 13.7% on semaglutide (Wegovy) after 72 weeks. Individual results vary, though, and Wegovy has an approved heart-risk benefit that Zepbound does not yet have. Your doctor can weigh both against your health history.
What is the difference between Zepbound and Mounjaro?
Zepbound and Mounjaro contain the same active drug, tirzepatide, made by Eli Lilly. Mounjaro is approved to control blood sugar in adults with type 2 diabetes. Zepbound is approved for chronic weight management and for obstructive sleep apnea in adults with obesity. The split mirrors Ozempic and Wegovy, which share semaglutide but carry different approved uses.
How much does Zepbound cost without insurance?
As of October 2026, LillyDirect lists Zepbound self-pay prices at $299 a month for the 2.5 mg dose, $399 for 5 mg and $449 for 7.5 mg to 15 mg if you refill within 45 days. Otherwise, higher doses cost $499 to $699 a month. Prices can change, so check the maker page or your pharmacy before you fill.
Which GLP-1 has the fewest side effects?
No GLP-1 is side-effect free, and trials have not shown a clear winner. Semaglutide and tirzepatide share the same common effects, mainly nausea, diarrhea, vomiting and constipation, usually during dose increases. Pills are not automatically gentler; in the Wegovy pill trial, 74% reported gut symptoms. Starting low and raising the dose slowly, as labeled, helps many people.
Can I switch from Ozempic or Wegovy to Zepbound?
Switching is possible, but only with your prescriber guiding it. They are different molecules with different dosing schedules, so your doctor will choose a starting dose and timing based on your current dose and side effects. Insurance may also need a new prior authorization. Never combine two GLP-1 drugs, and do not convert doses on your own.
Related health guides
- GLP-1 drugs: what they do to your body
- Walking vs running for fat loss
- How to lose belly fat
- Metabolic flexibility explained
- Best foods for gut health
- Longevity habits that add up
By Elizabeth Brown, health and wellness writer. Sources: FDA, MedlinePlus (NIH), CMS and Medicare.gov, NEJM and JAMA trial reports via PubMed, Novo Nordisk and Eli Lilly price pages. Last reviewed for accuracy: October 21, 2026.
Disclaimer: This article is for informational purposes only and is not medical advice. It does not replace diagnosis or treatment from a qualified healthcare provider. Talk to your doctor before starting, stopping or changing any medication. If you think you are having a medical emergency, call 911.
